L 52/26
EN
Official Journal of the European Union
20.2.2023
ANNEX VIII
Infection with Rift valley fever virus (RVF) PART 1 SPECIFIC CONDITIONS FOR THE IMPLEMENTATION OF EMERGENCY PROTECTIVE VACCINATION FOR PREVENTION AND CONTROL OF RVF
1.
Size of the vaccination zone: 50 km radius around affected establishments or ring vaccination between 20 and 50 km. 2.
Size of the peri-vaccination zone: No specific rules. 3.
Type of vaccine to be used or prioritised: Inactivated vaccines.
Live attenuated vaccines may only be used in endemic areas. 4.
Minimum coverage: No specific rules. 5.
Targeted animals/species: Animals of listed species in accordance with Implementing Regulation (EU) 2018/1882 kept in the vaccination zone, including at least bovine, ovine, caprine and camelid animals.
PART 2 SPECIFIC CONDITIONS FOR THE REINFORCED CLINICAL AND LABORATORY SURVEILLANCE TO BE IMPLEMENTED IN THE VACCINATION AND PERI-VACCINATION ZONES DURING EMERGENCY PROTECTIVE VACCINATION FOR PREVENTION AND CONTROL OF RVF
Passive surveillance: in the vaccination and peri-vaccination zones, enhanced passive surveillance on abortions, stillbirths and neonatal mortality during summer and autumn (during the peak of and end of the vector season).
PART 3 SPECIFIC CONDITIONS FOR THE PROHIBITION OF MOVEMENTS OF ANIMALS AND PRODUCTS AND FOR GRANTING A DEROGATION IN ACCORDANCE WITH ARTICLE 13, IN A VACCINATION ZONE WHERE EMERGENCY PROTECTIVE VACCINATION FOR PREVENTION AND CONTROL OF RVF IS CARRIED OUT
1.
Animals and products subject to prohibition of movements: vaccinated animals and products thereof, including semen, embryos and oocytes destined to be moved to other Member States. 2.
Germinal products subject to prohibition of collection: semen, oocytes and embryo from animals of listed species. 3.
Conditions for granting a derogation in accordance with Article 13(2), point (b)(ii), Article 13(3), point (b), and Article 13(4), point (b).
Movements that may be authorised.
Movements of vaccinated animals and products thereof, including semen, embryos and oocytes to another Member State for which the competent authority of the Member State of destination grants a specific authorisation for entry of each consignment of vaccinated animals or products thereof.
This authorisation may be based on the results of laboratory examinations.
PART 4 RECOVERY PERIODS FOR RVF
No additional disease-specific requirements